D1 PAM I Synthesis Using Chiral Intermediates and Flow Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethenone (D1 PAM I) suffer from low yields, high costs, and inefficiencies, including numerous steps, impurities, and the use of expensive and difficult-to-source starting materials.
Innovation Solution
A novel synthetic route involving sequential treatments with reducing agents, mild mineral bases, and transition metal halides, coupled with flow reaction methodology, to achieve improved yields and stereoselectivity, reducing the number of steps and utilizing commercially available intermediates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the existing 11-step synthetic route is used, then the synthesis can be completed with commercially available starting materials, but the overall yield is low (about 17%) and production is inefficient
Solution Approach 1:
The patent divides the synthesis into two main routes: Route A (8 steps from L-DOPA) and Route B (10 steps from (S)-(+)-benzyl glycidyl ether). This segmentation allows optimization of specific synthetic pathways to improve overall yield and efficiency compared to the existing 11-step route
Solution Approach 2:
The patent employs preliminary chiral resolution and stereoselective reactions to establish correct stereochemistry early in the synthesis. For example, Route A uses L-DOPA as a chiral starting material, and Route B uses (S)-(+)-benzyl glycidyl ether, eliminating the need for later chiral resolution steps and improving overall yield
2Ease of manufacture
If the existing synthetic route is used, then the process can be implemented with standard reagents, but the production cost is high and time-consuming
Solution Approach 1:
The patent extracts and eliminates unnecessary intermediate steps from the existing synthesis. Route A achieves the target in 8 steps by directly converting L-DOPA through key transformations, while Route B achieves it in 10 steps from commercially available (S)-(+)-benzyl glycidyl ether, both reducing the existing 11 steps and production time
Solution Approach 2:
The patent changes key reaction parameters including using flow reaction methodology for certain steps, employing specific catalysts (e.g., ZrCl4 for Pictet-Spengler cyclization), and optimizing reaction conditions to reduce time while maintaining ease of manufacture
3Ease of manufacture
If the existing route is used, then the synthesis can proceed with available reagents, but impurity profiles are high and purity is low
Solution Approach 1:
The patent introduces specific intermediary compounds with well-defined stereochemistry to mediate the synthesis. Route A uses L-DOPA as a chiral intermediary that ensures correct stereochemistry throughout, and Route B uses (S)-(+)-benzyl glycidyl ether and subsequent chiral auxiliaries, reducing impurity formation while maintaining reagent availability
Solution Approach 2:
The patent replaces mechanical separation and purification methods with stereoselective chemical reactions that inherently produce higher purity products. For example, using enzymatic resolutions and stereoselective catalysis instead of repeated chromatographic purifications
4Ease of manufacture
If commercially available starting materials are used, then the ease of manufacture is improved, but the number of synthetic steps remains high
Solution Approach 1:
The patent makes the starting materials multi-functional by choosing compounds that provide multiple features needed for the final product. L-DOPA provides chiral center, aromatic ring, and amino group in one compound. Similarly, (S)-(+)-benzyl glycidyl ether provides chiral center and functional groups for subsequent transformations, reducing the number of steps from commercially available materials
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new process achieves higher overall yields, reduces production time and costs, and facilitates efficient production of D1 PAM I with improved purity and stereoselectivity, making it suitable for commercial production.
Implementation Method 1
Sequential treatment of (R)-2-bromophenylalanine with a reducing agent and iodine
Implementation Method 2
Pictet-Spengler cyclization of (4R)-3-[(1S)-1-(arylsulfonyl)ethyl]-4-[(2-bromophenyl)methyl]oxazolidin-2-one with a transition metal halide
Implementation Method 3
coupled with flow reaction methodology, to achieve improved yields and stereoselectivity
Data Source
AI summary
The embodiments of the present invention provide processes and intermediates for the preparation of D1 PAM I: Formula (I).